Intralymphatic Allergen Immunotherapy (ILIT) in grass pollen allergy: a randomized controlled trial

Condition studied

allergic diseases (allergic rhinosinusitis, allergic asthma, allergy to Hymenoptera venoms)

Investigational medicinal product(s)

Eligibility

Primary endpoint

1. Symptom scores (SS) (primary endpoint), ranging from 0 to 18 points, with 3 nasal and 3 ocular symptoms (runny nose, blocked nose, sneezing, red eyes, itchy eyes and watery eyes), each of which scored from 0 (no symptoms) to 3 (severe symptoms);, 2. Medication scores (MS), taking into account the exact number of anti-histamine tablets, nasal corticosteroid puffs, eye drops, 3. Rhino-conjunctivitis Quality of Life Questionnaire (RQLQ)